Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCSG 45: Pre-operative carboplatin + olaparib vs TAC in HRD-positive triple-negative breast cancer
2024-512821-10-00Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib and carboplatin in breast cancer (3 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoints: Histo-pathological response by residual cancer burden (RCB) and Adverse events in substudy. Started Apr 2024; status: completed.
02
Drugs
olaparibcarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512821-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512821-10-00.